Wall Street Analysts Are Neutral on Top Healthcare Picks
Analysts fell to the sidelines weighing in on Cardinal Health (CAH – Research Report) and MacroGenics (MGNX – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cardinal Health (CAH)
Deutsche Bank analyst George Hill maintained a Hold rating on Cardinal Health on February 20. The company’s shares closed last Monday at $224.82.
According to TipRanks.com, Hill is a 4-star analyst with an average return of
Currently, the analyst consensus on Cardinal Health is a Strong Buy with an average price target of $249.92, representing an 11.4% upside. In a report issued on February 5, TipRanks – Google also downgraded the stock to Hold with a $223.00 price target.
See today’s best-performing stocks on TipRanks >>
MacroGenics (MGNX)
In a report released today, Stephen Willey from Stifel Nicolaus reiterated a Hold rating on MacroGenics, with a price target of $4.00. The company’s shares closed last Monday at $1.75, close to its 52-week low of $1.26.
According to TipRanks.com, Willey is a 4-star analyst with an average return of
Currently, the analyst consensus on MacroGenics is a Hold with an average price target of $4.00.
